Christian Hollweg

christian.hollweg@lw.com

+1.858.509.8497

Profile

Christian Hollweg advises emerging growth companies and venture capital investors involved in the life sciences, technology, and other growth industries.

Christian combines extensive transactional experience with an entrepreneurial mindset to counsel clients across the full company lifecycle – from formation to exit – on a wide range of matters, including:

Company formation and structuring
Equity and debt financings
Corporate governance
Restructurings
Mergers, acquisitions, and other exit strategies
Initial public offerings

He works closely with founders, management and investors to understand their goals and provide practical legal and strategic advice. Christian leverages the full resources of Latham’s global platform to address key issues in cross-border transactions.

While in law school, Christian co-founded the UCLA School of Law’s Law and Entrepreneurship Association and served as its treasurer, served as an academic scholar for the UCLA Law Fellows Program, and worked as a graduate assistant tutor for the law school’s Academic Support Program.

Experience

Christian’s experience includes advising:

Crystalys Therapeutics, a biopharmaceutical company, in its US$205 million Series A financing, co-led by Novo Holdings, SR One, and Catalys Pacific
Timberlyne Therapeutics, a biopharmaceutical company, in its US$180 million Series A financing and concurrent exclusive license from KeyMed Biosciences
Clarify Health, a cloud analytics and value-based payments platform company, in its US$150 million Series D financing, led by SoftBank Vision Fund 2
Endeavor BioMedicines, a biotechnology company, in its US$132.5 million Series C financing
Mineralys Therapeutics, a biopharmaceutical company, in its US$118 million Series B financing led by RA Capital and Andera Partners
Lead investor Avenir Growth in the US$111 million Series B financing of Chile-based Xepelin, a provider of B2B payments and financial services for SMBs in Latin America, which resulted in the largest Series B financing round in Chile’s history at the time
CG Oncology, an oncolytic immunotherapy, in its US$105 million Series F financing, co-led by Foresite Capital and TCGX; and earlier CG Oncology’s US$120 million Series E financing, co-led by ORI Capital, Longitude Capital and Decheng Capital
Zerigo Health, a digital health company, in its US$43 million Series B financing
NewLimit, a biotechnology company, in its US$40 million Series A financing, led by Dimension, Founders Fund, and Kleiner Perkins
Convex, a software company, in its US$39 million Series B financing, led by Fifth Wall, Emergence Capital, and GGV
Ocelot Bio, a biopharmaceutical company, in its US$36 million Series A financing, led by Venrock Partners, Vivo Capital, and RA Capital
Medallion, a technology company, in its US$35 million Series C financing, led by Spark Capital and GV (formerly Google Ventures)
Molecular Assemblies, developing an enzymatic DNA synthesis technology, in its US$29 million Series B financing